F2G
Develops first-in-class antifungal medicines for rare, life-threatening fungal infections in patients with limited options
Highlights
- New on EvolcAdded 2026-10-28
About F2G
F2G is a biotechnology company developing novel antifungal therapeutics for rare, life-threatening fungal infections. Its lead candidate, derived from a chemical series called the F3 series, has received FDA Breakthrough Therapy Designation for two indications and entered phase 3 clinical trials in 2021.
The company's customers are patients with rare invasive fungal infections who have few or no treatment options. The website describes a collaboration with Shionogi Co., Ltd. to develop and commercialise a novel antifungal agent; the revenue model is not otherwise described.
F2G was originally founded as Functional Fungal Genomics in 1998 and is registered in the United Kingdom, with its headquarters in Macclesfield. The leadership team and board include executives and non-executive directors, and the company is supported by a group of investors. Careers listings cover scientific, commercial, manufacturing and G&A roles.
Product: Investigational first-in-class antifungal drug candidate for rare invasive fungal infections
Jobs at F2G
Leadership
- Francesco Maria Lavino · Chief Executive OfficerSource: company website
- John H. Rex · Chief Medical OfficerSource: company website
- Mark Baglin · Chief Commercial OfficerSource: company website
- Mike Birch · Chief Operating OfficerSource: company website
- Ralf Schmid · Chief Financial OfficerSource: company website
- Sandy Parkes · Vice President, Human ResourcesSource: company website
More biotech & pharma companies
Flyttr
Pest biosecurity platform with sensors, AI decision-support and biological countermeasures for governments and agricultureNew on EvolcFortress Diagnostics
In vitro diagnostic tests and reagents for clinical laboratories, healthcare providers and research institutions worldwideNew on EvolcGenedrive PLC
Point-of-care pharmacogenetic tests for NHS clinicians, including antibiotic and antiplatelet treatment kitsNew on EvolcGenomics
Genomic analytics and disease-risk tools for pharmaceutical companies, healthcare providers, employers and individualsRemote-friendlyhameln pharma
Generic injectable medicines for hospitals, pharmacies and palliative care in more than 45 countriesNew on EvolcRemote-friendly
Website technologies
Older, unverified list. Detection dates and supporting evidence are not yet available.
- Elementor
- Matomo
- WordPress
- jQuery
- nginx